11:20 AM
 | 
Jun 15, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of improving postural stability as measured by mean changes from baseline in body sway vs. zolpidem ER. Data were presented at the Associated Professional Sleep Societies meeting in Baltimore.

The double-blind,...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >